Junshi Bio announced that the new indication for the use of Teriprizumab monoclonal antibody in combination with paclitaxel for first-line treatment of PD-L1-positive relapsed or metastatic triple-negative breast cancer has been approved by the National Medical Products Administration. This is the tenth indication approved for Teriprizumab monoclonal antibody in mainland China.
君实生物：特瑞普利单抗新适应症获批
Junshi Bio: Teriprizumab monoclonal antibody approved for a new indication
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.